|
[1] PARK PH, SANZ-GARCIA C, NAGY LE. Adiponectin as ananti-fibrotic and anti-inflammatory adipokine in the liver[J].Curr Pathobiol Rep, 2015, 3 (4) :243-252.
|
|
[2] DUVAL F, MORENO-CUEVAS JE, GONZLEZ-GANZA MT, etal. Liver fibrosis and protection mechanisms action of medicinalplants targeting apoptosis of hepatocytes and hepatic stellatecells[J]. Adv Pharmacol Sci, 2014, 2014:373295.
|
|
[3] SAXENA NK, ANANIA FA. Adipocytokines and hepatic fibrosis[J]. Trends Endocrinol Metab, 2015, 26 (3) :153-161.
|
|
[4] ABENAVOLI L, PETA V. Role of adipokines and cytokines innon-alcoholic fatty liver disease[J]. Rev Recent Clin Trials, 2014, 9 (3) :134-140.
|
|
[5] SILVA TE, COLOMBO G, SCHIAVON LL. Adiponectin:A mul-titasking player in the field of liver diseases[J]. DiabetesMetab, 2014, 40 (2) :95-107.
|
|
[6] HU E, LIANG P, SPIEGELMAN BM. AdipoQ is a novel adi-pose-specific gene dysregulated in obesity[J]. J BiolChem, 1996, 271 (18) :10697-10703.
|
|
[7] BOUTARI C, PERAKAKIS N, MANTZOROS CS. Association ofadipokines with development and progression of nonalcoholicfatty liver disease[J]. Endocrinol Metab (Seoul) , 2018, 33 (1) :33-43.
|
|
[8] GAMBERI T, MAGHERINI F, MODESTI A, et al. Adiponectinsignaling pathways in liver diseases[J]. Biomedicines, 2018, 6 (2) :e52.
|
|
[9] LIM JY, OH MA, KIM WH, et al. AMP-activated protein ki-nase inhibits TGF-β-induced fibrogenic responses of hepat-ic stellate cells by targeting transcriptional coactivator p300[J]. J Cell Physiol, 2012, 227 (3) :1081-1089.
|
|
[10] SHAFIEI MS, SHETTY S, SCHERER PE, et al. Adiponectinregulation of stellate cell activation via PPARγ-dependentand-independent mechanisms[J]. Am J Pathol, 2011, 178 (6) :2690-2699.
|
|
[11] XIN X, YAN HZ, LI WQ, et al. Studies on PPARαandγpar-ticipating in progression of liver fibrosis by regulating ASCL1[J]. J Clin Hepatol, 2014, 30 (8) :833-835. (in Chinese) 辛萱, 颜红柱, 李维卿, 等.过氧化物酶体增殖物激活受体α、γ调控长链酰基辅酶A合成酶1对肝纤维化进程的影响[J].临床肝胆病杂志, 2014, 30 (8) :833-835.
|
|
[12] RM M, WANG J, HO V, et al. Adiponectin reduces hepaticstellate cell migration by promoting tissue inhibitor of metallo-proteinase-1 (TIMP-1) secretion[J]. J Biol Chem, 2015, 290 (9) :5533-5542.
|
|
[13] HANDY JA, SAXENA NP, LIN S, et al. Adiponectin activationof AMPK disrupts leptin-mediated hepatic fibrosis via sup-pressors of cytokine signaling (SOCS-3) [J]. J Cell Bio-chem, 2010, 112 (2) :1195-1207.
|
|
[14] KUMAR P, SMITH T, RAHMAN K, et al. Adiponectin modu-lates focal adhesion disassembly in activated hepatic stellatecells:Implication for reversing hepatic fibrosis[J]. FASEB J, 2014, 28 (12) :5172-5183.
|
|
[15] KAMADA Y, TAMURA S, KISO S, et al. Enhanced carbon tet-rachloride-induced liver fibrosis in mice lacking adiponectin[J]. Gastroenterology, 2003, 125 (6) :1796-1807.
|
|
[16] ASANO T, WATANABE K, KUBOTA N, et al. Adiponectinknockout mice on high fat diet develop fibrosing steatohepati-tis[J]. J Gastroenterol Hepatol, 2009, 24 (10) :1669-1676.
|
|
[17] KUMAR P, SMITH T, RAHMAN K, et al. Adiponectin agonistADP355 attenuates CCl4-induced liver fibrosis in mice[J].PLo S One, 2014, 9 (10) :e110405.
|
|
[18] ZHANG W, WU R, ZHANG F, et al. Thiazolidinediones im-prove hepatic fibrosis in rats with non-alcoholic steatohepati-tis by activating the adenosine monophosphate-activatedprotein kinase signalling pathway[J]. Clin Exp PharmacolPhysiol, 2012, 39 (12) :1026-1033.
|
|
[19] DA ST, COSTA-SILVA M, CORREA CG, et al. Clinical signif-icance of serum adiponectin and resistin levels in liver cirrhosis[J]. Ann Hepatol, 2018, 17 (2) :286-299.
|
|
[20] TRIANTAFYLLOU GA, PASCHOU SA, MANTZOROS CS. Lep-tin and hormones:Energy homeostasis[J]. Endocrinol MetabClin North Am, 2016, 45 (3) :633-645.
|
|
[21] MEEK TH, MORTON GJ. The role of leptin in diabetes:Meta-bolic effects[J]. Diabetologia, 2016, 59 (5) :928-932.
|
|
[22] ZHAO ZB, LI JF, HUANG SS, et al. The advances of profi-brogenic research of leptin and its signaling pathways in he-patic fibrosis[J]. J Clin Hepatol, 2011, 27 (10) :1106-1108. (in Chinese) 赵正斌, 李俊峰, 黄双盛, 等.瘦素及其信号通路促肝纤维化机制研究进展[J].临床肝胆病杂志, 2011, 27 (10) :1106-1108.
|
|
[23] POLYZOS SA, KOUNTOURAS J, MANTZOROS CS. Leptin innonalcoholic fatty liver disease:A narrative review[J]. Metab-olism, 2015, 64 (1) :60-78.
|
|
[24] MUNZBERG H, MORRISON CD. Structure, production andsignaling of leptin[J]. Metabolism, 2015, 64 (1) :13-23.
|
|
[25] GE HY, ZHANG SH. Research advances in association be-tween matrix metalloproteinases and liver fibrosis[J]. J ClinHepatol, 2017, 33 (3) :563-566. (in Chinese) 戈宏焱, 张仕华.基质金属蛋白酶与肝纤维化关系的研究进展[J].临床肝胆病杂志, 2017, 33 (3) :563-566.
|
|
[26] GUI X, SUN L, GU L, et al. Leptin promotes pulmonary fibro-sis development by inhibiting autophagy via PI3K/Akt/m TORpathway[J]. Biochem Biophys Res Commun, 2018, 498 (3) :660-666.
|
|
[27] ZHOU Q, GUAN W, QIAO H, et al. GATA binding protein 2mediates leptin inhibition of PPARγ1 expression in hepatic stel-late cells and contributes to hepatic stellate cell activation[J].Biochim Biophys Acta, 2014, 1842 (12) :2367-2377.
|
|
[28] HANDY JA, FU PP, KUMAR P, et al. Adiponectin inhibits lep-tin signalling via multiple mechanisms to exert protectiveeffects against hepatic fibrosis[J]. Biochem J, 2011, 440 (3) :385-395.
|
|
[29] BUECHLER C, HABERL EM, REINFISCHBOECK L, et al. Adi-pokines in liver cirrhosis[J]. Int J Mol Sci, 2017, 18 (7) :1392.
|
|
[30] KASZTELANSZCZERBINSKA B, SURDACKA A, SLOMKA M, et al. Association of serum adiponectin, leptin, and resistinconcentrations with the severity of liver dysfunction and thedisease complications in alcoholic liver disease[J]. MediatorsInflamm, 2013, 2013 (3) :148526.
|
|
[31] SADIK NA, AHMED A, AHMED S. The significance of serumlevels of adiponectin, leptin, and hyaluronic acid in hepatocel-lular carcinoma of cirrhotic and noncirrhotic patients[J]. HumExp Toxicol, 2012, 31 (4) :311-321.
|
|
[32] VIKRANT R, BORHANI AA, DUNN MA, et al. Serum leptin isa biomarker of malnutrition in decompensated cirrhosis[J].PLo S One, 2016, 11 (9) :e0159142.
|
|
[33] BEIER JI, ARTEEL GE. Alcoholic liver disease and the poten-tial role of plasminogen activator inhibitor-1 and fibrin metabo-lism[J]. Exp Biol Mde, 2012, 237 (1) :1-9.
|
|
[34] GHOSH AK, VAUGHAN DE. PAI-1 in tissue fibrosis[J]. J CellPhysiol, 2012, 227 (2) :493-507.
|
|
[35] BAECK C, WEI X, BARTNECK M, et al. Pharmacological inhi-bition of the chemokine C-C motif chemokine ligand 2 (mon-ocyte chemoattractant protein 1) accelerates liver fibrosis re-gression by suppressing Ly-6C+macrophage infiltration inmice[J]. Hepatology, 2014, 59 (3) :1060-1072.
|
|
[36] LI Y, DING L, HASSAN W, et al. Adipokines and hepatic in-sulin resistance[J]. J Diabetes Res, 2013, 2013:170532.
|
|
[37] NOBILI V, CARPINO G, ALISI A, et al. Hepatic progenitorcells activation, fibrosis, and adipokines production in pediat-ric nonalcoholic fatty liver disease[J]. Hepatology, 2012, 56 (6) :2142-2153.
|
|
[38] DONG ZX, SU L, BRYMORA J, et al. Resistin mediates thehepatic stellate cell phenotype[J]. World J Gastroenterol, 2013, 19 (28) :4475-4485.
|
|
[39] KRIST J, WIEDER K, KLOTING N, et al. Effects of weight lossand exercise on apelin serum concentrations and adipose tis-sue expression in human obesity[J]. Obesity Facts, 2013, 6 (1) :57-69.
|
|
[40] NAN YM, KONG LB, REN WG, et al. Activation of peroxisomeproliferator activated receptor alpha ameliorates ethanol medi-ated liver fibrosis in mice[J]. Lipids Health Dis, 2013, 12 (1) :11.
|
|
[41] REN RZ, ZHANG X, XU J, et al. Chronic ethanol consumptionincreases the levels of chemerin in the serum and adipose tis-sue of humans and rats[J]. Acta Pharmacol Sin, 2012, 33 (5) :652-659.
|
|
[42] WU MS, NING CL, LIU KZ. The research progress of Chemerin[J]. Med Recap, 2016, 22 (11) :2102-2106. (in Chinese) 吴孟水, 宁翠利, 刘宽芝. Chemerin的研究进展[J].医学综述, 2016, 22 (11) :2102-2106.
|
|
[43] DOCKE S, LOCK JF, BIRKENFELD AL, et al. Elevated hepat-ic chemerin mRNA expression in human non-alcoholic fattyliver disease[J]. Eur J Endocrinol, 2013, 169 (5) :547-557.
|
|
[44] EISINGER K, KRAUTBAUER S, WIEST R, et al. Portal veinomentin is increased in patients with liver cirrhosis but is notassociated with complications of portal hypertension[J]. Eur JClin Invest, 2013, 43 (9) :926-932.
|
DownLoad: